Biocon Ltd Stock Price Today (NSE: BIOCON)
Fundamental Score
Biocon Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Biocon Ltd share price today is ₹360.90, down 2.52% on NSE/BSE as of 30 March 2026. Biocon Ltd (BIOCON) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹52.76K (Cr). The 52-week high for BIOCON share price is ₹424.95 and the 52-week low is ₹299.00. At a P/E ratio of 111.20x, BIOCON is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 4.76% and a debt-to-equity ratio of 0.62.
Biocon Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Biocon Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Biocon Share Price Analysis: A Growth Strategist's Perspective
The pharmaceutical industry, known for its lengthy and costly drug development cycles, often sees periods of both explosive growth and significant regulatory headwinds. In this landscape, understanding a company's financial health is crucial. This analysis examines the current standing of Biocon share price (₹365.3999938964844) with a focus on its financial metrics and competitive positioning.
Biocon's current Price-to-Earnings (PE) ratio of 111.2 suggests the market has high expectations for future earnings growth. However, this valuation needs to be contextualized against its Return on Capital Employed (ROCE) of 6.25%. While positive, a ROCE of 6.25% may indicate limitations in Biocon's ability to generate strong returns from its investments. This, in turn, could affect the company's economic moat, impacting its ability to sustain a competitive advantage over the long term.
Comparing Biocon with its sector peers offers further insights. Consider
Mankind Pharma Ltd, a company often recognized for its robust management quality. A deep dive into the management's strategic decisions and execution capabilities compared to Biocon’s, as evidenced through consistent revenue growth and operational efficiencies, could provide clarity on Biocon's potential for improvement. Other peers, such as Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd, can be evaluated through similar performance metrics.It's important to acknowledge that this assessment is a snapshot in time, based solely on publicly available data, and forms a part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra. Factors like evolving regulatory landscapes, clinical trial outcomes, and patent expirations can significantly influence the company's trajectory. The 6.25% ROCE should also be scrutinized for its consistency, improvement, and comparison against industry standards to understand its true bearing on the long term dominance of Biocon Ltd.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Biocon Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BIOCON across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (21.68%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (486.23%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (19.64%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (19.11% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Cash Generation (₹1570.00 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (54.45%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 28.67%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Below-Average Return on Equity (4.76%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.25%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 111.20x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Interest Coverage (1.90x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Biocon Ltd Financial Statements
Comprehensive financial data for Biocon Ltd including income statement, balance sheet and cash flow
About BIOCON (Biocon Ltd)
Biocon Ltd is a global biopharmaceutical innovator, deeply rooted in the Indian subcontinent yet reaching across continents with its diverse portfolio of life-saving medicines. The... company navigates the complex landscape of modern healthcare, pushing boundaries in research and development while striving to make treatments more accessible and affordable. From its state-of-the-art manufacturing facilities, Biocon formulates, produces, and distributes advanced therapies designed to combat a range of chronic and debilitating illnesses. With a keen focus on cutting-edge science and ethical practices, Biocon aspires to improve patient outcomes worldwide, contributing to a healthier future for all. Biocon's impact extends beyond simply manufacturing pharmaceuticals; it's about shaping the future of healthcare through pioneering biosimilar development and innovative solutions. At the core of Biocon's operations lies a commitment to tackling some of the most pressing health challenges facing the global population. This drive has led to the creation of a robust pipeline of generic formulations and active pharmaceutical ingredients (APIs), targeting critical therapeutic areas. These include cardiovascular diseases, diabetes, obesity, multiple sclerosis, and a range of cancers. Biocon's scientific teams work relentlessly to develop and refine these medicines, ensuring both efficacy and affordability. The company's unwavering dedication to innovation, paired with a robust global distribution network, enables Biocon to make a meaningful difference in the lives of countless patients around the world. Through strategic partnerships and a patient-centric approach, Biocon continues to address unmet medical needs and democratize access to essential medicines. Beyond generics and APIs, Biocon has emerged as a frontrunner in the development and commercialization of biosimilars. These biologics, offering similar efficacy and safety profiles to their reference counterparts, promise to revolutionize treatment options and provide cost-effective alternatives for patients. Biocon's biosimilar portfolio includes treatments for diabetes and oncology, reflecting the company's strategic focus on high-impact therapeutic areas. By leveraging its expertise in complex protein engineering and biomanufacturing, Biocon aims to lower the financial burden of biologic therapies, improving access for patients worldwide. With a strong emphasis on regulatory compliance and quality standards, Biocon is committed to establishing biosimilars as a cornerstone of accessible and sustainable healthcare.
Company Details
Key Leadership
Corporate Events
BIOCON Share Price: Frequently Asked Questions
What is the current share price of Biocon Ltd (BIOCON)?
As of 30 Mar 2026, 12:07 pm IST, Biocon Ltd share price is ₹360.90. The BIOCON stock has a market capitalisation of ₹52.76K (Cr) on NSE/BSE.
Is BIOCON share price Overvalued or Undervalued?
BIOCON share price is currently trading at a P/E ratio of 111.20x, compared to the industry average of 31.77x. Based on this relative valuation, the Biocon Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of BIOCON share price?
The 52-week high of BIOCON share price is ₹424.95 and the 52-week low is ₹299.00. These values are updated daily from NSE/BSE price data.
What factors affect the Biocon Ltd share price?
Key factors influencing BIOCON share price include quarterly earnings growth (Sales Growth: 19.64%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Biocon Ltd a good stock for long-term investment?
Biocon Ltd shows a 5-year Profit Growth of 7.16% and an ROE of 4.76%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.62 before investing in BIOCON shares.
How does Biocon Ltd compare with its industry peers?
Biocon Ltd competes with major peers in the Pharmaceuticals. Investors should compare BIOCON share price P/E of 111.20x and ROE of 4.76% against the industry averages to determine competitive standing.
What is the P/E ratio of BIOCON and what does it mean?
BIOCON share price has a P/E ratio of 111.20x compared to the industry average of 31.77x. Investors pay ₹111 for every ₹1 of annual earnings.
How is BIOCON performing according to Bull Run's analysis?
BIOCON has a Bull Run fundamental score of 50.9/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does BIOCON belong to?
BIOCON operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Biocon Ltd share price.
What is Return on Equity (ROE) and why is it important for BIOCON?
BIOCON has an ROE of 4.76%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Biocon Ltd generates profits from shareholders capital.
How is BIOCON debt-to-equity ratio and what does it indicate?
BIOCON has a debt-to-equity ratio of 0.62, which indicates moderate leverage that should be monitored.
What is BIOCON dividend yield and is it a good dividend stock?
BIOCON offers a dividend yield of 0.13%, meaning you receive ₹0.13 annual dividend for every ₹100 invested in Biocon Ltd shares.
How has BIOCON share price grown over the past 5 years?
BIOCON has achieved 5-year growth rates of: Sales Growth 19.11%, Profit Growth 7.16%, and EPS Growth 7.15%.
What is the promoter holding in BIOCON and why does it matter?
Promoters hold 54.45% of BIOCON shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Biocon Ltd.
What is BIOCON market capitalisation category?
BIOCON has a market capitalisation of ₹52763 crores, placing it in the Large-cap category.
How volatile is BIOCON stock?
BIOCON has a beta of N/A. A beta > 1 suggests the Biocon Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is BIOCON operating profit margin trend?
BIOCON has a 5-year average Operating Profit Margin (OPM) of 21.68%, indicating the company's operational efficiency.
How is BIOCON quarterly performance?
Recent quarterly performance shows Biocon Ltd YoY Sales Growth of 19.64% and YoY Profit Growth of 486.23%.
What is the institutional holding pattern in BIOCON?
BIOCON has FII holding of 6.61% and DII holding of 22.06%. Significant institutional holding often suggests professional confidence in the Biocon Ltd stock.